Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis

被引:27
作者
Pilcer, Gabrielle [1 ]
De Bueger, Veronique [1 ]
Traina, Karl [2 ]
Traore, Hamidou [3 ]
Sebti, Thami [3 ]
Vanderbist, Francis [3 ]
Amighi, Karim [1 ]
机构
[1] ULB, Lab Pharmaceut & Biopharmaceut, Brussels, Belgium
[2] APTIS, Liege, Belgium
[3] Labs SMB SA, Brussels, Belgium
关键词
Dry powder inhaler (DPI); Antibiotics; Tobramycin; Clarithromycin; Spray-drying; Carrier free; PSEUDOMONAS-AERUGINOSA; DRUG-DELIVERY; PHARMACOKINETIC EVALUATION; BIOFILM MODEL; TOBRAMYCIN; CLARITHROMYCIN; FORMULATIONS; MACROLIDES; PARTICLES; ERYTHROMYCIN;
D O I
10.1016/j.ijpharm.2013.04.069
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to develop an efficient combination antibiotic formulation containing tobramycin and clarithromycin as a dry powder for inhalation. A carrier-free formulation of the two drugs was produced by spray-drying and characterised for its aerodynamic behaviour by impaction tests with an NGI and release profiles. The particle size distribution, morphological evaluation and crystallinity state were determined by laser diffraction, scanning electron microscopy and powder X-ray diffraction, respectively. Drug deposition profiles were similar for the two antibiotics, which has a synergistic effect, allowing them to reach the target simultaneously at the expected dose. The release profiles show that tobramycin and clarithromycin should probably dissolve without any difficulties in vivo in the lung as 95% of tobramycin and 57% of clarithromycin mass dissolved in 10 min for the spray-dried formulation. The FPF increased from 35% and 31% for the physical blend for tobramycin and clarithromycin, respectively, to 65% and 63% for the spray-dried formulation. The spray-dried formulation shows particularly high deposition results, even at sub-optimal inspiratory flow rates, and therefore, represents an attractive alternative in the local treatment of lung infection such as in cystic fibrosis. (c) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:112 / 120
页数:9
相关论文
共 43 条
[1]   ENHANCED ACTIVITY OF COMBINATION OF TOBRAMYCIN AND PIPERACILLIN FOR ERADICATION OF SESSILE BIOFILM CELLS OF PSEUDOMONAS-AERUGINOSA [J].
ANWAR, H ;
COSTERTON, JW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1666-1671
[2]   The inhalation device influences lung deposition and bronchodilating effect of terbutaline [J].
Borgstrom, L ;
Derom, E ;
Stahl, E ;
WahlinBoll, E ;
Pauwels, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (05) :1636-1640
[3]   Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability [J].
Buyck, Julien M. ;
Plesiat, Patrick ;
Traore, H. ;
Vanderbist, F. ;
Tulkens, Paul M. ;
Van Bambeke, Francoise .
CLINICAL INFECTIOUS DISEASES, 2012, 55 (04) :534-542
[4]   Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers .1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance [J].
deBoer, AH ;
Winter, HMI ;
Lerk, CF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 130 (02) :231-244
[5]   Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients [J].
Depreter, F. ;
Burniat, A. ;
Blocklet, D. ;
Lacroix, S. ;
Cnop, M. ;
Fery, F. ;
Van Aelst, N. ;
Pilcer, G. ;
Deleers, M. ;
Goldman, S. ;
Amighi, K. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (01) :4-13
[6]   Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration [J].
Depreter, Flore ;
Amighi, Karim .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 76 (03) :454-463
[7]   Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin [J].
Eckert, Randal ;
Brady, Keith M. ;
Greenberg, E. Peter ;
Qi, Fengxia ;
Yarbrough, Daniel K. ;
He, Jian ;
McHardy, Ian ;
Anderson, Maxwell H. ;
Shi, Wenyuan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) :3833-3838
[8]   Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis [J].
Geller, DE ;
Pitlick, WH ;
Nardella, PA ;
Tracewell, WG ;
Ramsey, BW .
CHEST, 2002, 122 (01) :219-226
[9]   Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa [J].
Giamarellos-Bourboulis, EJ ;
Antonopoulou, A ;
Raftogiannis, M ;
Koutoukas, P ;
Tsaganos, T ;
Tziortzioti, V ;
Panagou, C ;
Adamis, T ;
Giamarellou, H .
BMC INFECTIOUS DISEASES, 2006, 6 (1)
[10]   Pathophysiology and management of pulmonary infections in cystic fibrosis [J].
Gibson, RL ;
Burns, JL ;
Ramsey, BW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (08) :918-951